Pharmaceutical Executive November 18, 2021
Jill Wechsler, Pharm Exec’s Washington Correspondent

Leading legislators have launched the campaign to enact a second version of the 21st Century Cures Act, building on the landmark measure approved by Congress in 2016. Reps. Diana DeGette (D-CO) and Fred Upton (R-MI) again have teamed up to advance a comprehensive (170 pages) bill that would provide billions to establish the new Advanced Research Projects Agency for Health (ARPA-H), enhance pandemic preparedness, and provide added authorities and resources for FDA.1 Many of its provisions have been applauded by the medical community and biopharma manufacturers, but enactment is not likely any time soon, as a host of legislative priorities already are backing up on Capitol Hill.

A likely scenario is that next year, Cures 2.0 will be incorporated into...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Cures Act, FDA, Govt Agencies, Healthcare System, Pharma / Biotech, Public Health / COVID
What Washington wants in Cures 2.0
How ONC Can Strengthen Its HTI-1 Rule To Ensure Transparency, Fairness, And Equity In AI
Providers Take Note: The Common Agreement Version 2.0 Released
Advancing Nationwide, Trusted Health Information Networks
Cures Act tied to quicker release, access of imaging reports

Share This Article